Pharmaceutical Efficacy of Gypenoside LXXV on Non-Alcoholic Steatohepatitis (NASH)

Ginsenosides have offered a wide array of beneficial roles in the pharmacological regulation of hepatic metabolic syndromes, including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), and obesity. Of the numerous ginsenosides, Rg3 has been widely investigated, but the...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Jin Ha Lee, Ji Young Oh, Soo Hyun Kim, In Jeong Oh, Yong-ho Lee, Keun Woo Lee, Woong Hee Lee, Jeong-Hwan Kim
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2020-10-01
Edice:	Biomolecules
Témata:	ginsenosides gypenoside LXXV drug discovery liver fibrosis nonalcoholic steatohepatitis (NASH) hepatic stellate cells
On-line přístup:	https://www.mdpi.com/2218-273X/10/10/1426
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!